-
1
-
-
0034614637
-
The hallmarks of cancer
-
D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70
-
(2000)
Cell
, vol.100
, pp. 57-70
-
-
Hanahan, D.1
Weinberg, R.A.2
-
2
-
-
0036274359
-
The fundamental role of epigenetic events in cancer
-
PA Jones SB Baylin 2002 The fundamental role of epigenetic events in cancer Nat Rev Genet 3 415 428
-
(2002)
Nat Rev Genet
, vol.3
, pp. 415-428
-
-
Jones, P.A.1
Baylin, S.B.2
-
3
-
-
0036144048
-
DNA methylation patterns and epigenetic memory
-
A Bird 2002 DNA methylation patterns and epigenetic memory Genes Dev 16 6 21
-
(2002)
Genes Dev
, vol.16
, pp. 6-21
-
-
Bird, A.1
-
4
-
-
0034610814
-
The language of covalent histone modifications
-
BD Strahl CD Allis 2000 The language of covalent histone modifications Nature 403 41 45
-
(2000)
Nature
, vol.403
, pp. 41-45
-
-
Strahl, B.D.1
Allis, C.D.2
-
5
-
-
0035839136
-
Translating the histone code
-
T Jenuwein CD Allis 2001 Translating the histone code Science 293 1074 1080
-
(2001)
Science
, vol.293
, pp. 1074-1080
-
-
Jenuwein, T.1
Allis, C.D.2
-
6
-
-
21244467166
-
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
-
KN Bhalla 2005 Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies J Clin Oncol 23 3971 3993
-
(2005)
J Clin Oncol
, vol.23
, pp. 3971-3993
-
-
Bhalla, K.N.1
-
7
-
-
0242624636
-
Epigenetic targets in hematopoietic malignancies
-
R Claus M Lubbert 2003 Epigenetic targets in hematopoietic malignancies Oncogene 22 6489 6496
-
(2003)
Oncogene
, vol.22
, pp. 6489-6496
-
-
Claus, R.1
Lubbert, M.2
-
8
-
-
0030897009
-
International scoring system for evaluating prognosis in myelodysplastic syndromes
-
P Greenberg C Cox MM LeBeau 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088
-
(1997)
Blood
, vol.89
, pp. 2079-2088
-
-
Greenberg, P.1
Cox, C.2
Lebeau, M.M.3
-
9
-
-
0345357773
-
Gene silencing in cancer in association with promoter hypermethylation
-
JG Herman SB Baylin 2003 Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2042 2054
-
(2003)
N Engl J Med
, vol.349
, pp. 2042-2054
-
-
Herman, J.G.1
Baylin, S.B.2
-
10
-
-
0035962631
-
DNA methylation, methyltransferases, and cancer
-
KD Robertson 2001 DNA methylation, methyltransferases, and cancer Oncogene 20 3139 3155
-
(2001)
Oncogene
, vol.20
, pp. 3139-3155
-
-
Robertson, K.D.1
-
11
-
-
0036733675
-
Chromatin modification and epigenetic reprogramming in mammalian development
-
E Li 2002 Chromatin modification and epigenetic reprogramming in mammalian development Nat Rev Genet 3 662 673
-
(2002)
Nat Rev Genet
, vol.3
, pp. 662-673
-
-
Li, E.1
-
12
-
-
0032574977
-
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
-
X Nan HH Ng CA Johnson 1998 Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 393 386 389
-
(1998)
Nature
, vol.393
, pp. 386-389
-
-
Nan, X.1
Ng, H.H.2
Johnson, C.A.3
-
13
-
-
0141502199
-
INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia
-
INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia Leukemia 17 1813 1819
-
(2003)
Leukemia
, vol.17
, pp. 1813-1819
-
-
Christiansen, D.H.1
Andersen, M.K.2
Pedersen-Bjergaard, J.3
-
14
-
-
0033179375
-
Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
-
JR Melki PC Vincent SJ Clark 1999 Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia Cancer Res 59 3730 3740
-
(1999)
Cancer Res
, vol.59
, pp. 3730-3740
-
-
Melki, J.R.1
Vincent, P.C.2
Clark, S.J.3
-
15
-
-
10744233452
-
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
-
JP Issa G Garcia-Manero FJ Giles 2004 Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 1635 1640
-
(2004)
Blood
, vol.103
, pp. 1635-1640
-
-
Issa, J.P.1
Garcia-Manero, G.2
Giles, F.J.3
-
17
-
-
0942276838
-
Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes
-
MT Voso A Scardocci F Guidi 2004 Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes Blood 103 698 700
-
(2004)
Blood
, vol.103
, pp. 698-700
-
-
Voso, M.T.1
Scardocci, A.2
Guidi, F.3
-
18
-
-
24944476696
-
Hypermethylation of the suppressor of cytokine signalling-1(SOCS-1) in myelodysplastic syndrome
-
K Brakensiek F Länger B Schlegelberger H Kreipe U Lehmann 2005 Hypermethylation of the suppressor of cytokine signalling-1(SOCS-1) in myelodysplastic syndrome Br J Haematol 130 209 217
-
(2005)
Br J Haematol
, vol.130
, pp. 209-217
-
-
Brakensiek, K.1
Länger, F.2
Schlegelberger, B.3
Kreipe, H.4
Lehmann, U.5
-
19
-
-
17144366936
-
Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia
-
MF Johan DT Bowen ME Frew AC Goodeve JT Reilly 2005 Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia Br J Haematol 129 60 65
-
(2005)
Br J Haematol
, vol.129
, pp. 60-65
-
-
Johan, M.F.1
Bowen, D.T.2
Frew, M.E.3
Goodeve, A.C.4
Reilly, J.T.5
-
20
-
-
33744924582
-
CpG island methylation is a poor prognostic factor in myelodysplastic syndrome patients and is reversed by decitabine therapy: Results of a phase III randomized study
-
[abstract]. Abstract 790.
-
Shen L, Kantarjian H, Saba H, et al. CpG island methylation is a poor prognostic factor in myelodysplastic syndrome patients and is reversed by decitabine therapy: results of a phase III randomized study [abstract]. Blood 2005;106. Abstract 790.
-
(2005)
Blood
, vol.106
-
-
Shen, L.1
Kantarjian, H.2
Saba, H.3
-
21
-
-
0742269866
-
Decitabine
-
JP Issa 2003 Decitabine Curr Opin Oncol 15 446 451
-
(2003)
Curr Opin Oncol
, vol.15
, pp. 446-451
-
-
Issa, J.P.1
-
22
-
-
0015511621
-
Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-azacytidine
-
A Cihák J Vesely 1972 Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-azacytidine Biochem Pharmacol 21 3257 3265
-
(1972)
Biochem Pharmacol
, vol.21
, pp. 3257-3265
-
-
Cihák, A.1
Vesely, J.2
-
23
-
-
0022244733
-
Azapyrimidine nucleosides: Metabolism and inhibitory mechanisms
-
ák A Cih J Vesely J Skoda 1985 Azapyrimidine nucleosides: metabolism and inhibitory mechanisms Adv Enzyme Regul 24 335 354
-
(1985)
Adv Enzyme Regul
, vol.24
, pp. 335-354
-
-
Cih, Á.A.1
Vesely, J.2
Skoda, J.3
-
25
-
-
0020032366
-
Inhibition of DNA methyltrans-ferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′- deoxycytidine
-
F Creusot G Acs JK Christman 1982 Inhibition of DNA methyltrans-ferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine J Biol Chem 257 2041 2048
-
(1982)
J Biol Chem
, vol.257
, pp. 2041-2048
-
-
Creusot, F.1
Acs, G.2
Christman, J.K.3
-
26
-
-
0014871518
-
Phase specificity of 5-azacytidine against mammalian cells in tissue culture
-
LH Li EJ Olin TJ Fraser BK Bhuyan 1970 Phase specificity of 5-azacytidine against mammalian cells in tissue culture Cancer Res 30 2770 2775
-
(1970)
Cancer Res
, vol.30
, pp. 2770-2775
-
-
Li, L.H.1
Olin, E.J.2
Fraser, T.J.3
Bhuyan, B.K.4
-
27
-
-
0014872738
-
Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia
-
LH Li EJ Olin HH Buskirk LM Reineke 1970 Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia Cancer Res 30 2760 2769
-
(1970)
Cancer Res
, vol.30
, pp. 2760-2769
-
-
Li, L.H.1
Olin, E.J.2
Buskirk, H.H.3
Reineke, L.M.4
-
28
-
-
0037068379
-
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy
-
JK Christman 2002 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy Oncogene 21 5483 5495
-
(2002)
Oncogene
, vol.21
, pp. 5483-5495
-
-
Christman, J.K.1
-
29
-
-
0018860957
-
Cellular differentiation, cytidine analogs and DNA methylation
-
PA Jones SM Taylor 1980 Cellular differentiation, cytidine analogs and DNA methylation Cell 20 85 93
-
(1980)
Cell
, vol.20
, pp. 85-93
-
-
Jones, P.A.1
Taylor, S.M.2
-
30
-
-
0035988868
-
Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors
-
A Aparicio JS Weber 2002 Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors Curr Opin Investig Drugs 3 627 633
-
(2002)
Curr Opin Investig Drugs
, vol.3
, pp. 627-633
-
-
Aparicio, A.1
Weber, J.S.2
-
31
-
-
0022303520
-
Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia
-
RL Momparler GE Rivard M Gyger 1985 Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia Pharmacol Ther 30 277 286
-
(1985)
Pharmacol Ther
, vol.30
, pp. 277-286
-
-
Momparler, R.L.1
Rivard, G.E.2
Gyger, M.3
-
32
-
-
0019857236
-
Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia
-
GE Rivard RL Momparler J Demers 1981 Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia Leuk Res 5 453 462
-
(1981)
Leuk Res
, vol.5
, pp. 453-462
-
-
Rivard, G.E.1
Momparler, R.L.2
Demers, J.3
-
33
-
-
0027309013
-
Pilot study of 5-aza-2-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results
-
MC Petti F Mandelli V Zagonel 1993;7(Supp Pilot study of 5-aza-2-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results Leukemia 1) 36 41
-
(1993)
Leukemia
, vol.1
, pp. 36-41
-
-
Petti, M.C.1
Mandelli, F.2
Zagonel, V.3
-
34
-
-
0030985020
-
Decitabine studies in chronic and acute myelogenous leukemia
-
HM Kantarjian SM O'Brien E Estey 1997;11(Supp Decitabine studies in chronic and acute myelogenous leukemia Leukemia 1) S35 S36
-
(1997)
Leukemia
, vol.1
-
-
Kantarjian, H.M.1
O'Brien, S.M.2
Estey, E.3
-
35
-
-
0030965033
-
A randomized phase II study on the effects of 5-aza-2-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study (06893)
-
R Willemze S Suciu E Archimbaud 1997;11(Supp A randomized phase II study on the effects of 5-aza-2-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893) Leukemia 1) S24 S27
-
(1997)
Leukemia
, vol.1
-
-
Willemze, R.1
Suciu, S.2
Archimbaud, E.3
-
36
-
-
0027221806
-
5-Aza-2-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes
-
V Zagonel Re G Lo G Marotta 1993;7(Supp 5-Aza-2-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes Leukemia 1) 30 35
-
(1993)
Leukemia
, vol.1
, pp. 30-35
-
-
Zagonel, V.1
Lo Re, G.2
Marotta, G.3
-
37
-
-
0031042482
-
Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome
-
PW Wijermans JW Krulder PC Huijgens P Neve 1997 Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome Leukemia 11 1 5
-
(1997)
Leukemia
, vol.11
, pp. 1-5
-
-
Wijermans, P.W.1
Krulder, J.W.2
Huijgens, P.C.3
Neve, P.4
-
38
-
-
17444452612
-
Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
-
P Wijermans M Lubbert G Verhoef 2000 Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 956 962
-
(2000)
J Clin Oncol
, vol.18
, pp. 956-962
-
-
Wijermans, P.1
Lubbert, M.2
Verhoef, G.3
-
39
-
-
33646071894
-
Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
-
H Kantarjian JP Issa CS Rosenfeld 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794 1803
-
(2006)
Cancer
, vol.106
, pp. 1794-1803
-
-
Kantarjian, H.1
Issa, J.P.2
Rosenfeld, C.S.3
-
40
-
-
33846011361
-
Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia
-
H Kantarjian Y Oki G Garcia-Manero 2007 Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 52 57
-
(2007)
Blood
, vol.109
, pp. 52-57
-
-
Kantarjian, H.1
Oki, Y.2
Garcia-Manero, G.3
-
41
-
-
33745968917
-
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
-
BD Cheson PL Greenberg JM Bennett 2006 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 419 425
-
(2006)
Blood
, vol.108
, pp. 419-425
-
-
Cheson, B.D.1
Greenberg, P.L.2
Bennett, J.M.3
-
43
-
-
0017136745
-
A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlympho-cytic leukemia
-
JA Levi PH Wiernik 1976 A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlympho-cytic leukemia Cancer 38 36 41
-
(1976)
Cancer
, vol.38
, pp. 36-41
-
-
Levi, J.A.1
Wiernik, P.H.2
-
44
-
-
0021258302
-
A randomized comparison of postremission therapy in acute myelogenous leukemia: A Southeastern Cancer Study Group trial
-
WR Vogler EF Winton DS Gordon MR Raney B Go L Meyer 1984 A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial Blood 63 1039 1045
-
(1984)
Blood
, vol.63
, pp. 1039-1045
-
-
Vogler, W.R.1
Winton, E.F.2
Gordon, D.S.3
Raney, M.R.4
Go, B.5
Meyer, L.6
-
47
-
-
0017082530
-
5-Azacytidine: A new anti-cancer drug with effectiveness in acute myelogenous leukemia
-
DD Von Hoff M Slavik FM Muggia 1976 5-Azacytidine: a new anti-cancer drug with effectiveness in acute myelogenous leukemia Ann Intern Med 85 237 245
-
(1976)
Ann Intern Med
, vol.85
, pp. 237-245
-
-
Von Hoff, D.D.1
Slavik, M.2
Muggia, F.M.3
-
48
-
-
0025825531
-
Toxicity trials of amsacrine (AMSA) and etopo-side +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): A pilot study
-
CP Steuber T Holbrook B Camitta VJ Land C Sexauer J Krischer 1991 Toxicity trials of amsacrine (AMSA) and etopo-side +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study Invest New Drugs 9 181 184
-
(1991)
Invest New Drugs
, vol.9
, pp. 181-184
-
-
Steuber, C.P.1
Holbrook, T.2
Camitta, B.3
Land, V.J.4
Sexauer, C.5
Krischer, J.6
-
49
-
-
0020466344
-
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ tha-lassemia
-
TJ Ley J DeSimone NP Anagnou 1982 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ tha-lassemia N EnglJ Med 307 1469 1475
-
(1982)
N EnglJ Med
, vol.307
, pp. 1469-1475
-
-
Ley, T.J.1
Desimone, J.2
Anagnou, N.P.3
-
50
-
-
0004959517
-
Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with non-random hypomethylation of DNA around the ã-ä-β-globin gene complex
-
S Charache G Dover K Smith CC Talbot M Moyer S Boyer 1983 Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with non-random hypomethylation of DNA around the ã-ä-β-globin gene complex Proc NatlAcad Sci USA 80 4842 4846
-
(1983)
Proc NatlAcad Sci USA
, vol.80
, pp. 4842-4846
-
-
Charache, S.1
Dover, G.2
Smith, K.3
Talbot, C.C.4
Moyer, M.5
Boyer, S.6
-
51
-
-
0027154222
-
Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
-
LR Silverman JF Holland RS Weinberg 1993;7(Supp Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes Leukemia 1) 21 29
-
(1993)
Leukemia
, vol.1
, pp. 21-29
-
-
Silverman, L.R.1
Holland, J.F.2
Weinberg, R.S.3
-
52
-
-
0037093195
-
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia GroupB
-
LR Silverman EP Demakos BL Peterson 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia GroupB J Clin Oncol 20 2429 2440
-
(2002)
J Clin Oncol
, vol.20
, pp. 2429-2440
-
-
Silverman, L.R.1
Demakos, E.P.2
Peterson, B.L.3
-
53
-
-
21044439177
-
Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes
-
E Kaminskas A Farrell S Abraham 2005 Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes Clin Cancer Res 11 3604 3608
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3604-3608
-
-
Kaminskas, E.1
Farrell, A.2
Abraham, S.3
-
54
-
-
33748474416
-
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
-
LR Silverman DR McKenzie BL Peterson 2006 Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 3895 3903
-
(2006)
J Clin Oncol
, vol.24
, pp. 3895-3903
-
-
Silverman, L.R.1
McKenzie, D.R.2
Peterson, B.L.3
-
55
-
-
38849152987
-
Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy
-
[abstract]. Abstract 518.
-
Borthakur G, Ravandi-Kashani F, Cortes J, et al. Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy [abstract].Blood 2006;108. Abstract 518.
-
(2006)
Blood
, vol.108
-
-
Borthakur, G.1
Ravandi-Kashani, F.2
Cortes, J.3
-
56
-
-
0037108309
-
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment
-
M Daskalakis TT Nguyen C Nguyen 2002 Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′- deoxycytidine (decitabine) treatment Blood 100 2957 2964
-
(2002)
Blood
, vol.100
, pp. 2957-2964
-
-
Daskalakis, M.1
Nguyen, T.T.2
Nguyen, C.3
-
57
-
-
33745714230
-
Combined DNA methyltrans-ferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
-
SD Gore S Baylin E Sugar 2006 Combined DNA methyltrans-ferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Res 66 6361 6369
-
(2006)
Cancer Res
, vol.66
, pp. 6361-6369
-
-
Gore, S.D.1
Baylin, S.2
Sugar, E.3
-
58
-
-
57849105832
-
Hypomethylation induction and molecular response after decitabine therapy in chronic myelomonocytic leukemia (CMML)
-
[abstract]. Abstract 2322.
-
Oki Y, Jelinek J, Kantarjian H, Issa JP. Hypomethylation induction and molecular response after decitabine therapy in chronic myelomonocytic leukemia (CMML) [abstract].Blood 2006;108. Abstract 2322.
-
(2006)
Blood
, vol.108
-
-
Oki, Y.1
Jelinek, J.2
Kantarjian, H.3
Issa, J.P.4
-
59
-
-
0036861629
-
DNA methyltransferase inhibitors: State of the art
-
J Goffin E Eisenhauer 2002 DNA methyltransferase inhibitors: state of the art Ann Oncol 13 1699 1716
-
(2002)
Ann Oncol
, vol.13
, pp. 1699-1716
-
-
Goffin, J.1
Eisenhauer, E.2
-
60
-
-
0032842834
-
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase
-
M Wilhelm S O'Brien MB Rios 1999 Phase I study of arabinosyl-5- azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase Leuk Lymphoma 34 511 518
-
(1999)
Leuk Lymphoma
, vol.34
, pp. 511-518
-
-
Wilhelm, M.1
O'Brien, S.2
Rios, M.B.3
-
61
-
-
0036965821
-
Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases
-
L Zhou X Cheng BA Connolly MJ Dickman PJ Hurd DP Hornby 2002 Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases J Mol Biol 321 591 599
-
(2002)
J Mol Biol
, vol.321
, pp. 591-599
-
-
Zhou, L.1
Cheng, X.2
Connolly, B.A.3
Dickman, M.J.4
Hurd, P.J.5
Hornby, D.P.6
-
63
-
-
0030797585
-
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
-
W Gu RG Roeder 1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 90 595 606
-
(1997)
Cell
, vol.90
, pp. 595-606
-
-
Gu, W.1
Roeder, R.G.2
-
64
-
-
0346688568
-
Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation
-
K Watamoto M Towatari Y Ozawa 2003 Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation Oncogene 22 9176 9184
-
(2003)
Oncogene
, vol.22
, pp. 9176-9184
-
-
Watamoto, K.1
Towatari, M.2
Ozawa, Y.3
-
66
-
-
0032760819
-
Leukemogenesis by CBF oncoproteins
-
AD Friedman 1999 Leukemogenesis by CBF oncoproteins Leukemia 13 1932 1942
-
(1999)
Leukemia
, vol.13
, pp. 1932-1942
-
-
Friedman, A.D.1
-
67
-
-
33646002067
-
Chemistry and biology of chromatin remodeling agents: State of art and future perspectives of HDAC inhibitors
-
M Rodriquez M Aquino I Bruno Martino G De M Taddei L Gomez-Paloma 2006 Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors Curr Med Chem 13 1119 1139
-
(2006)
Curr Med Chem
, vol.13
, pp. 1119-1139
-
-
Rodriquez, M.1
Aquino, M.2
Bruno, I.3
De Martino, G.4
Taddei, M.5
Gomez-Paloma, L.6
-
68
-
-
17744416444
-
Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites
-
Y Sowa T Orita S Minamikawa 1997 Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites Biochem Biophys Res Commun 241 142 150
-
(1997)
Biochem Biophys Res Commun
, vol.241
, pp. 142-150
-
-
Sowa, Y.1
Orita, T.2
Minamikawa, S.3
-
69
-
-
33644883611
-
Histone deacetylase inhibitor apicidin induces cyclin e expression through Sp1 sites
-
S Kim JK Kang YK Kim 2006 Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites Biochem Biophys Res Commun 342 1168 1173
-
(2006)
Biochem Biophys Res Commun
, vol.342
, pp. 1168-1173
-
-
Kim, S.1
Kang, J.K.2
Kim, Y.K.3
-
70
-
-
9744223645
-
Histone deacetylase inhibitor trichostatin a represses estrogen receptor β-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines
-
JP Alao EW Lam S Ali 2004 Histone deacetylase inhibitor trichostatin A represses estrogen receptor β-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines Clin Cancer Res 10 8094 8104
-
(2004)
Clin Cancer Res
, vol.10
, pp. 8094-8104
-
-
Alao, J.P.1
Lam, E.W.2
Ali, S.3
-
71
-
-
33644836891
-
Histone deacetylase inhibitor, trichostatin a induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells
-
JP Alao AV Stavropoulou EW Lam RC Coombes DM Vigushin 2006 Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells Mol Cancer 5 8 8
-
(2006)
Mol Cancer
, vol.5
, pp. 8-8
-
-
Alao, J.P.1
Stavropoulou, A.V.2
Lam, E.W.3
Coombes, R.C.4
Vigushin, D.M.5
-
72
-
-
5144222440
-
WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells
-
WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells Biochem Biophys Res Commun 324 860 867
-
(2004)
Biochem Biophys Res Commun
, vol.324
, pp. 860-867
-
-
Li, H.1
Wu, X.2
-
73
-
-
0034737290
-
Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF
-
HS Zhang M Gavin A Dahiya 2000 Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF Cell 101 79 89
-
(2000)
Cell
, vol.101
, pp. 79-89
-
-
Zhang, H.S.1
Gavin, M.2
Dahiya, A.3
-
74
-
-
0037377060
-
Ubiquitination, phosphorylation and acetyla-tion: The molecular basis for p53 regulation
-
CL Brooks W Gu 2003 Ubiquitination, phosphorylation and acetyla-tion: the molecular basis for p53 regulation Curr Opin Cell Biol 15 164 171
-
(2003)
Curr Opin Cell Biol
, vol.15
, pp. 164-171
-
-
Brooks, C.L.1
Gu, W.2
-
75
-
-
1642490813
-
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
-
L Fuino P Bali S Wittmann 2003 Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 971 984
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 971-984
-
-
Fuino, L.1
Bali, P.2
Wittmann, S.3
-
76
-
-
0043016178
-
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells
-
R Nimmanapalli L Fuino P Bali 2003 Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells Cancer. Res. 63 5126 5135
-
(2003)
Cancer. Res.
, vol.63
, pp. 5126-5135
-
-
Nimmanapalli, R.1
Fuino, L.2
Bali, P.3
-
77
-
-
33748427812
-
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
-
TJ Gaymes RA Padua M Pla 2006 Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 4 563 573
-
(2006)
Mol Cancer Res
, vol.4
, pp. 563-573
-
-
Gaymes, T.J.1
Padua, R.A.2
Pla, M.3
-
78
-
-
20044390016
-
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
-
JS Ungerstedt Y Sowa WS Xu 2005 Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors Proc NatlAcad Sci USA 102 673 678
-
(2005)
Proc NatlAcad Sci USA
, vol.102
, pp. 673-678
-
-
Ungerstedt, J.S.1
Sowa, Y.2
Xu, W.S.3
-
79
-
-
0041347519
-
Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?
-
RW Johnstone JD Licht 2003 Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 13 18
-
(2003)
Cancer Cell
, vol.4
, pp. 13-18
-
-
Johnstone, R.W.1
Licht, J.D.2
-
80
-
-
25144487124
-
Mechanisms of selective anticancer action of histone deacetylase inhibitors
-
A Insinga S Minucci PG Pelicci 2005 Mechanisms of selective anticancer action of histone deacetylase inhibitors Cell Cycle 4 741 743
-
(2005)
Cell Cycle
, vol.4
, pp. 741-743
-
-
Insinga, A.1
Minucci, S.2
Pelicci, P.G.3
-
81
-
-
33845209109
-
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and micro-tubule stabilization in papillary serous endometrial cancer cells
-
SC Dowdy S Jiang XC Zhou 2006 Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and micro-tubule stabilization in papillary serous endometrial cancer cells Mol Cancer Ther 5 2767 2776
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 2767-2776
-
-
Dowdy, S.C.1
Jiang, S.2
Zhou, X.C.3
-
82
-
-
33749031527
-
Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer
-
I Friedmann A Atmaca KU Chow E Jager E eidmann 2006 Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer J Chemother 18 415 420
-
(2006)
J Chemother
, vol.18
, pp. 415-420
-
-
Friedmann, I.1
Atmaca, A.2
Chow, K.U.3
Jager, E.4
Eidmann, E.5
-
83
-
-
0033615547
-
Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase
-
GD Kim YH Choi A Dimtchev SJ Jeong A Dritschilo M Jung 1999 Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase J Biol Chem 274 31127 31130
-
(1999)
J Biol Chem
, vol.274
, pp. 31127-31130
-
-
Kim, G.D.1
Choi, Y.H.2
Dimtchev, A.3
Jeong, S.J.4
Dritschilo, A.5
Jung, M.6
-
84
-
-
0032948005
-
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
-
EE Cameron KE Bachman S Myohanen JG Herman SB Baylin 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 103 107
-
(1999)
Nat Genet
, vol.21
, pp. 103-107
-
-
Cameron, E.E.1
Bachman, K.E.2
Myohanen, S.3
Herman, J.G.4
Baylin, S.B.5
-
85
-
-
33747874802
-
Histone deacetylase inhibitor trichostatin a and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells
-
J Bai A Demirjian J Sui W Marasco MP Callery 2006 Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells Biochem Biophys Res Commun 348 1245 1253
-
(2006)
Biochem Biophys Res Commun
, vol.348
, pp. 1245-1253
-
-
Bai, J.1
Demirjian, A.2
Sui, J.3
Marasco, W.4
Callery, M.P.5
-
86
-
-
4444309863
-
Treatment of myelodys-plastic syndromes with valproic acid alone or in combination withall-trans retinoic acid
-
A Kuendgen C Strupp M Aivado 2004 Treatment of myelodys-plastic syndromes with valproic acid alone or in combination withall-trans retinoic acid Blood 104 1266 1269
-
(2004)
Blood
, vol.104
, pp. 1266-1269
-
-
Kuendgen, A.1
Strupp, C.2
Aivado, M.3
-
87
-
-
33750530675
-
Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia
-
G Garcia-Manero HM Kantarjian B Sanchez-Gonzalez 2006 Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia Blood 108 3271 3279
-
(2006)
Blood
, vol.108
, pp. 3271-3279
-
-
Garcia-Manero, G.1
Kantarjian, H.M.2
Sanchez-Gonzalez, B.3
-
88
-
-
0037105374
-
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia
-
J Sierra WS Perez C Rozman 2002 Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia Blood 100 1997 2004
-
(2002)
Blood
, vol.100
, pp. 1997-2004
-
-
Sierra, J.1
Perez, W.S.2
Rozman, C.3
-
89
-
-
22344451414
-
Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome
-
SR Solomon BN Savani R Childs 2005 Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome Biol Blood Marrow Transplant 11 619 626
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 619-626
-
-
Solomon, S.R.1
Savani, B.N.2
Childs, R.3
-
90
-
-
33846953453
-
Myelodysplastic syndromes in patients younger than age 50
-
A Kuendgen C Strupp M Aivado 2006 Myelodysplastic syndromes in patients younger than age 50 J Clin Oncol 24 5358 5365
-
(2006)
J Clin Oncol
, vol.24
, pp. 5358-5365
-
-
Kuendgen, A.1
Strupp, C.2
Aivado, M.3
-
91
-
-
2142725956
-
Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation
-
J Cermak A Vitek K Michalova 2004 Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation Leuk Res 28 551 557
-
(2004)
Leuk Res
, vol.28
, pp. 551-557
-
-
Cermak, J.1
Vitek, A.2
Michalova, K.3
-
93
-
-
33746661102
-
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
-
R Martino S Iacobelli R Brand 2006 Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood 108 836 846
-
(2006)
Blood
, vol.108
, pp. 836-846
-
-
Martino, R.1
Iacobelli, S.2
Brand, R.3
-
94
-
-
0030729822
-
Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS: Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation
-
T De Witte A Van Biezen J Hermans 1997 Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS: Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation Blood 90 3853 3857
-
(1997)
Blood
, vol.90
, pp. 3853-3857
-
-
De Witte, T.1
Van Biezen, A.2
Hermans, J.3
-
95
-
-
33644553459
-
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
-
H Kantarjian M Beran J Cortes 2006 Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome Cancer 106 1099 1109
-
(2006)
Cancer
, vol.106
, pp. 1099-1109
-
-
Kantarjian, H.1
Beran, M.2
Cortes, J.3
-
96
-
-
0032884937
-
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
-
M Beran E Estey S O'Brien 1999 Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia J Clin Oncol 17 2819 2830
-
(1999)
J Clin Oncol
, vol.17
, pp. 2819-2830
-
-
Beran, M.1
Estey, E.2
O'Brien, S.3
-
97
-
-
0026481129
-
The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study
-
KB Miller K Kim FS Morrison 1992 The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study Ann Hematol 65 162 168
-
(1992)
Ann Hematol
, vol.65
, pp. 162-168
-
-
Miller, K.B.1
Kim, K.2
Morrison, F.S.3
-
98
-
-
27644562303
-
Low-dose cytosine ara-binoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
-
H Zwierzina S Suciu J Loeffler-Ragg 2005 Low-dose cytosine ara-binoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group Leukemia 19 1929 1933
-
(2005)
Leukemia
, vol.19
, pp. 1929-1933
-
-
Zwierzina, H.1
Suciu, S.2
Loeffler-Ragg, J.3
-
99
-
-
23844431694
-
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?
-
MA Sekeres A List 2005 Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good? Curr Hematol Rep 4 182 185
-
(2005)
Curr Hematol Rep
, vol.4
, pp. 182-185
-
-
Sekeres, M.A.1
List, A.2
-
100
-
-
2142712474
-
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
-
R Kurzrock M Albitar JE Cortes 2004 Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome J Clin Oncol 22 1287 1292
-
(2004)
J Clin Oncol
, vol.22
, pp. 1287-1292
-
-
Kurzrock, R.1
Albitar, M.2
Cortes, J.E.3
-
101
-
-
10744227474
-
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: Clinical and biologic activities in the phase 1 setting
-
R Kurzrock HM Kantarjian JE Cortes 2003 Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting Blood 102 4527 4534
-
(2003)
Blood
, vol.102
, pp. 4527-4534
-
-
Kurzrock, R.1
Kantarjian, H.M.2
Cortes, J.E.3
-
102
-
-
35148834657
-
Clofarabine is active in myelodysplastic syndrome (MDS)
-
[abstract]. Abstract 2660.
-
Faderl S, Gandhi V, O'Brien S, et al. Clofarabine is active in myelodysplastic syndrome (MDS) [abstract].Blood 2006;108. Abstract 2660.
-
(2006)
Blood
, vol.108
-
-
Faderl, S.1
Gandhi, V.2
O'Brien, S.3
-
103
-
-
4544267031
-
The role of angiogenesis in the biology and therapy of myelodysplastic syndromes
-
A Aguayo 2004 The role of angiogenesis in the biology and therapy of myelodysplastic syndromes Curr Hematol Rep 3 184 191
-
(2004)
Curr Hematol Rep
, vol.3
, pp. 184-191
-
-
Aguayo, A.1
-
104
-
-
0036172446
-
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
-
HJ Deeg J Gotlib C Beckham 2002 Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study Leukemia 16 162 164
-
(2002)
Leukemia
, vol.16
, pp. 162-164
-
-
Deeg, H.J.1
Gotlib, J.2
Beckham, C.3
-
105
-
-
33745002275
-
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
-
GJ Schiller J Slack JD Hainsworth 2006 Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes J Clin Oncol 24 2456 2464
-
(2006)
J Clin Oncol
, vol.24
, pp. 2456-2464
-
-
Schiller, G.J.1
Slack, J.2
Hainsworth, J.D.3
|